OBJECTIVE -Patient-physician race/ethnicity concordance can improve care for minority patients. However, its effect on cardiovascular disease (CVD) care and prevention is unknown. We examined associations of patient race/ethnicity and patient-physician race/ethnicity concordance on CVD risk factor levels and appropriate modification of treatment in response to high risk factor values (treatment intensification) in a large cohort of diabetic patients.
T
here are well-documented racial disparities in diabetes prevalence and mortality. African Americans and Hispanics have higher diabetes prevalence, death rates, and higher rates of serious complications (1). Even after controlling for access to care and socioeconomic status, diabetes disparities in the U.S. persist (1). There are also widely recognized disparities in cardiovascular risk factors associated with diabetes. African American and Hispanic patients with diabetes are less likely to meet glucose, cholesterol, or blood pressure targets (2).
The evidence surrounding whether insured patients of color receive worse care for diabetes and cardiovascular disease (CVD) risk factor control is mixed (3-6). Studies have found significant disparities in the likelihood of receipt of medications (7) and medication intensification (8, 9) . However, several studies have shown that minority patients received equal or better quality processes of care such as screening and medication intensification (4, 10 -12) .
Interpersonal barriers resulting from language or cultural differences between patients and physicians may explain a portion of diabetes management disparities (13, 14) . Physicians engage in less patient-centered communication with patients of color than with white patients (15) . Patient race/ethnicity has been associated with physicians' assessment of patient intelligence, feelings of affiliation toward the patient, and beliefs about the patients' likelihood of risk behavior and adherence with medical advice (16, 17) .
Patient-physician race/ethnicity concordance (the patient and health care provider having the same race/ethnicity) may help bridge interpersonal barriers in care for minority patients (18) . Race/ethnicity concordance is associated with increased patient trust in the physician (19) and health services utilization and satisfaction (20) . However, evidence that race/ethnicity concordance is an important factor in the quality of health care is mixed (21) . No studies have examined the association among race/ ethnicity concordance, cardiovascular disease processes of care, and levels of intermediate outcomes.
The purpose of this study was to examine the association of patient race/ ethnicity and patient-physician race/ ethnicity concordance on CVD risk factor levels and treatment intensification in a large cohort of diabetic patients in an integrated delivery system.
RESEARCH DESIGN AND
METHODS -Study participants were members of the Kaiser Permanente Northern California (KPNC) Diabetes
Registry in 2005. KPNC provides comprehensive medical care to ϳ3.2 million members. Patients were selected for the study if they had diabetes before 1 January 2005 and were enrolled with an active drug benefit continuously throughout 2005. Eligible patients were further assessed for the presence of hypertension and hyperlipidemia using Kaiser Permanente automated clinical databases. Selfreported race/ethnicity data, obtained from Kaiser Permanente member surveys, study surveys, and hospitalization data, were available for 87.3% of patients. Physician data were obtained from physician demographic files maintained by The Permanente Medical Group.
The final study population consisted of 108,555 African American, white, and Hispanic adult diabetic patients and 1,750 physicians. Asian patients were not included in this analysis because, with current data limitations, ethnically dissimilar Asian patients and physicians would be considered race/ethnicity concordant, despite potentially significant cultural and language differences.
Definition of dependent variables: good versus poor risk factor control Three measures of risk factor control were used as dependent variables in this study. Good A1C risk factor control for diabetes was defined as a patient having an A1C laboratory value of Ͻ8.0% throughout 2005; this level is in accordance with quality guidelines at KPNC. Good risk factor control for patients with hypertension was defined as not having two or more consecutive systolic blood pressure (SBP) readings Ͼ140 mmHg at any time during the year. This level is higher than that in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (22) and KPNC guidelines for diabetic patients of SBP Ͻ130 mmHg but is a conservative target at which a diabetic patient most likely needs therapy modification. Good risk factor control for patients with hyperlipidemia was defined as an LDL cholesterol value Ͻ100 mg/dl during the year (23 analyses were performed using STATA (version 10).
RESULTS -Approximately half of the patients in the sample were male (52%) and almost 97% reported speaking at least some English. Almost half of the patients (46%) were white, 11% were Hispanic, and 10% were African American. Spanish was the primary language of almost a quarter (22%) of the Hispanic patients. Only 10% of African American and 11% of Hispanic patients were in race/ ethnicity concordant relationships with their providers. Physicians were disproportionately white (47%) or Asian (40%); Ͻ8% of physicians were either African American or Hispanic. Patients were with their primary care physicians for an average of 5.6 -6.3 years (Table 1) . After controlling for patient and physician characteristics, patient race/ ethnicity was a significant predictor of risk factor control for all three risk factors (Table 2) . African American patients were less likely than whites to have A1C Ͻ8% (64 vs. 69%, P Ͻ 0.001). African American patients were also less likely to be at or below target LDL cholesterol (40 vs. 47%, P Ͻ 0.001) and SBP (70 vs. 78%, P Ͻ 0.001). Hispanic patients were less likely than whites to have A1C Ͻ8% (62 vs. 69%, P Ͻ 0.001). Risk factor control varied little and nonsignificantly by patientprovider race/ethnicity concordance (Table 3) . Table 4 shows the proportion of patients at above-target risk factor levels who received treatment intensification within 6 months, by race/ethnicity, after adjustment for patient and physician characteristics. Patient race/ethnicity was a significant predictor of treatment intensification for all three risk factors. African American patients were less likely than white patients to have A1C intensification (73 vs. 77%, P Ͻ 0.0001) and more likely to receive treatment intensification for SBP above target (78 vs. 71%, P Ͻ 0.0001). No significant differences in A1C or SBP intensification were found for Hispanic patients compared with white patients. However, Hispanic patients were more likely than white patients to have treatment intensification for LDL cholesterol (47 vs. 45%, P Ͻ 0.05). Treatment intensification was not significantly associated with patient-physician race/ ethnicity concordance (Table 5 ). Race/ ethnicity and race/ethnicity concordance effects on risk factor control and treatment intensification were consistent regardless of whether the patient's preferred language was included in the model, when cut points of A1C Ͻ7% and SBP Ͻ130 mmHg were used, and when insulin use was adjusted for in models of treatment intensification for hyperglycemia (data not shown).
CONCLUSIONS -Our findings are consistent with previous research showing racial disparities in CVD risk factor control (2). African American patients had worse risk factor control for A1C, LDL cholesterol, and SBP than white patients. Hispanic patients had worse control for A1C than white patients. Unlike previous research, after controlling for patient and physician characteristics, Hispanic patients were no more likely to have poor risk factor control for LDL cholesterol and SBP than white patients (3). Our findings also provide evidence supporting the hypothesis that race/ ethnicity is modestly associated with treatment intensification. We found disparities in A1C intensification in comparisons of African American patients with white patients. We also found that, in some cases, minority patients were more likely to receive treatment intensification than whites. One potential explanation for the greater likelihood of treatment intensification for African American patients with elevated SBP and Hispanics with elevated LDL cholesterol compared with whites is what is known as the statistical discrimination hypothesis: in instances of uncertainty, physicians may rely on what they know about the prevalence and consequences of the disease for the racial group to which a particular patient belongs (24) . Aware of high rates of hypertension in African American patients and high cholesterol in Hispanic patients, physicians may be more likely to intensify treatment.
Patient preferences may also drive differences in treatment intensification by race/ethnicity. Studies have shown differential trust in the medical system for minority patients. Minority patients are more likely than whites to perceive they would have received better medical care if they belonged to a different racial and ethnic group and that medical staff judged them unfairly or treated them with disrespect based on race/ethnicity (25) . These barriers to trust may affect patients' attitudes toward medicine and may contribute to differential reluctance to intensify therapy. On the other hand, it is also possible that African American patients may be more anxious about elevated SBP than white patients are.
Our findings do not support the hypothesis that patient-physician race/ ethnicity concordance would improve control of intermediate diabetes outcomes. Previous research has shown that equal or better care for minority patients does not necessarily close gaps in health outcomes between minority and white patients (13), so it is quite possible that potential benefits of concordance would not translate into (immediate) intermediate outcome improvement.
Several limitations to this study should be noted. Patients and physicians were from a single large, integrated health care delivery system; it is possible that patients and physicians in this setting may be different from patients and physicians in other settings. However, the patient and physician populations studied were fairly diverse, and the delivery system population is demographically similar to the region it serves (3). Omitted variables, such as patient family history of stroke, evidence of end-organ damage, and patient and physician attitudes and beliefs regarding medication, were not captured in these analyses and may influence differential intensification rates. Our variables were also limited by the fact that we only had access to socioeconomic status indicators from geocoding; individuallevel data on education and income were not available in this study. Another limitation is that we were unable to assess treatment intensification for A1C control in patients who were already taking insulin at the start of the study; it is possible that this causes underestimation of the level of intensification in this population and potentially biases differences in intensification rates for hyperglycemia by race/ethnicity. We were also unable to measure nonmedication treatment decisions physicians make; in response to poor control, physicians may provide diet, exercise, and other lifestyle recommendations that we are unable to include in our analysis.
Another limitation of the study was our inability to assess the impact of race/ ethnicity and race/ethnicity concordance on risk factor control and treatment intensification for Asians and patients and physicians of other races/ethnicities. Future research exploring ethnic and language concordance in these populations is indicated.
Finally, another potential reason we did not detect significant race/ethnicity interaction effects is that many diabetic patients also receive care from nutritionists, health educators, and pharmacists and potentially from other physicians and nurses. For example, patients may also have access to diabetes care classes provided by health educators. We were unable to assess patient race/ethnicity concordance with these and other medical care staff, and these relationships may have played a role in predicting risk factor control and intensification.
In summary, in this study, minority race/ethnicity was a significant predictor of worse patient risk factor control and better treatment intensification. However, patient-physician race/ethnicity concordance was not associated with either control or treatment intensification for any risk factor. Future researchers should try to illuminate the specific barriers to intensification, including possible patient or physician cultural factors that would inform targeted interventions to improve both risk factor control and treatment intensification.
